<DOC>
	<DOCNO>NCT02358681</DOCNO>
	<brief_summary>Ketorolac evidence-based , first-line acute migraine therapy commonly use pediatric population ; however , typically administer intravenous ( IV ) intramuscular ( IM ) rout , require painful distress needle stick administer . The intranasal ( IN ) route painless effective way administer analgesic , include ketorolac : IN ketorolac show effective analgesic adult painful condition , include acute migraine headache . However , IN ketorolac understudied child , know effective compare IV ketorolac , currently common way administer ketorolac child . If IN ketorolac show less effective IV ketorolac , IN ketorolac may viable painless alternative effectively treat acute migraine headache child . Therefore , primary aim demonstrate IN ketorolac non-inferior IV ketorolac reduce pain child acute migraine headache .</brief_summary>
	<brief_title>Intranasal Ketorolac Versus Intravenous Ketorolac Treatment Migraine Headaches Children</brief_title>
	<detailed_description>Primary Aim : Determine whether intranasal ( IN ) ketorolac non-inferior intravenous ( IV ) ketorolac reduce pain child acute migraine headache . We hypothesize IN ketorolac non-inferior IV ketorolac reduce acute migraine headache pain minimum clinically significant difference within 60 minute administration . Secondary Aim : Determine whether time achieve clinically significant reduction pain receiving IN ketorolac non-inferior IV ketorolac . We hypothesize IN ketorolac non-inferior IV ketorolac time take achieve clinically significant reduction pain . We conduct prospective , double-blinded , randomize , non-inferiority , parallel 1:1 clinical trial eligible child single urban pediatric ED . We block randomize patient receive either 1 mg/kg IN ketorolac IV placebo ( study group A ) , 0.5 mg/kg IV ketorolac IN placebo ( study group B ) . We assess patient 's pain baseline , 10-minute interval administration study drug 60 minute . The patient assess 2 hour 24 hour study drug administration outcomes related efficacy , function , safety .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>Present emergency department migraine headache define modify Irma criterion . The modified Irma criterion follow : Headache episodes 172 hour present least 3 follow 6 criterion : moderate severe episode impaired daily activity ; focal localization headache ; pulsatile description ; nausea vomit abdominal pain ; photophobia phonophobia avoidance light noise ; symptom increase activity resolve rest . Headache severity moderate severe pain ( i.e . least 4/10 Faces Pain Scale Revised ) Requiring IV ketorolac part headache treatment , per treat attend physician Contraindication receive ketorolac Receipt NSAID within six hour study drug administration Presence intranasal obstruction readily clear Inability speak English Spanish Unable complete selfreport measure pain questionnaire Critical illness Frequent use drug headache ( i.e . regular intake analgesic acute headache 10 day per month ) .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Intranasal</keyword>
	<keyword>Ketorolac</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Migraine</keyword>
	<keyword>Headache</keyword>
</DOC>